Form 4: Igor Bilinsky Trades IOVA Shares

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc., reported transactions involving restricted stock units and common stock.

Summary

• Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc. (IOVA), reported a transaction on June 1, 2026.
• This transaction involved the vesting of 8,790 Restricted Stock Units (RSUs), which were settled with 8,790 shares of common stock.
• Of these shares, 4,473 were withheld by the issuer to cover mandatory tax withholding requirements.
• The remaining 4,317 shares (8,790 - 4,473) were acquired by Mr. Bilinsky.
• Following these transactions, Mr. Bilinsky beneficially owns 134,556 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine equity compensation event with standard tax withholding, rather than a significant strategic move or a strong indicator of market sentiment.

Positives

• Vesting of 8,790 Restricted Stock Units (RSUs) indicates progress in equity compensation plans.
• Acquisition of 4,317 common shares by the Chief Operating Officer demonstrates continued investment in the company.

Negatives

• 4,473 shares were withheld by the issuer for tax purposes, reducing the net shares received by the reporting person.

Future Outlook

The filing indicates that remaining RSUs will vest in equal quarterly installments, suggesting a continued distribution of equity compensation over time.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive compensation and potential insider confidence. The withholding of shares for tax purposes is a common practice upon the vesting of equity awards.

Stakeholder Impact

• Shareholders gain insight into executive compensation and potential insider stock ownership changes.
• Employees may observe standard practices related to equity awards and tax implications.

Next Steps

• Continued vesting of RSUs in equal quarterly installments.

Key Dates

Keywords

IOVA, Iovance Biotherapeutics, Form 4, Insider Trading, Restricted Stock Units, RSUs, Common Stock, Executive Compensation, Tax Withholding